Glioblastoma (GBM), the most aggressive and common malignant brain tumor in adults, remains one of oncology’s most formidable challenges. Despite decades of research, the prognosis for patients remains grim, with most surviving only 12-18 months after diagnosis. Even with surgery, radiation, and chemotherapy, recurrence is almost inevitable, and patients with recurrent GBM (rGBM) face a median survival of just 6-10 months.
However, a groundbreaking dual-target CAR-T cell therapy developed by researchers at the University of Pennsylvania’s Perelman School of Medicine is offering new hope. In two landmark studies published in Nature Medicine (March 2024 and June 2025), the team demonstrated that targeting EGFR and IL13Rα2—two proteins commonly found in glioblastoma—can slow tumor growth in recurrent GBM patients, with some experiencing prolonged survival.
A New Approach: Dual-Target CAR-T Cells
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized cancer treatment, particularly in blood cancers like leukemia and lymphoma. However, solid tumors like glioblastoma have proven more difficult to treat due to their complex microenvironment and ability to evade immune detection.
To overcome these challenges, the Penn Medicine team engineered CART-EGFR-IL13Rα2, a novel CAR-T therapy that simultaneously attacks EGFR (found in 50-60% of GBM tumors) and IL13Rα2 (expressed in 50-75% of cases). Unlike traditional intravenous delivery, the therapy is administered intrathecally—directly into the cerebrospinal fluid—allowing the engineered T cells to reach brain tumors more effectively.
Phase 1 Trial Results: Encouraging Signs of Efficacy
The Phase 1 clinical trial enrolled 18 recurrent GBM patients who had undergone tumor resection. Key findings included:
- 62% of evaluable patients (8 out of 13) showed tumor regression, with one achieving a partial response and another maintaining stable disease for over 16 months.
- The median progression-free survival was 1.9 months, and the median overall survival had not yet been reached at the time of analysis (median follow-up: 8.1 months).
- Seven patients were still alive after one year, with one showing no tumor progression for over 16 months despite aggressive disease at enrollment.
- The maximum tolerated dose was established at 2.5×10⁷ CAR-T cells, with 56% of patients experiencing manageable Grade 3 neurotoxicity (no severe Grade 4-5 toxicities occurred).
Notably, CAR-T cells were detected in patients’ spinal fluid up to a year after treatment, suggesting long-term immune activity against the tumor. In one case, a patient who relapsed after therapy still showed T-cell infiltration and macrophage-driven tumor clearance in resected tissue—indicating an ongoing immune response.
Why This Matters
“Seeing tumors shrink in recurrent glioblastoma patients is unusual—past immunotherapies haven’t achieved this,” said the research team. “For a disease where survival is typically less than a year, having patients live 12 months or longer with stabilized disease is a major step forward.”
While this is still an early-stage trial, the results suggest that dual-target CAR-T therapy could become a viable option for recurrent GBM, a population with no effective treatments. The next steps include optimizing dosing, reducing neurotoxicity, and expanding trials to confirm efficacy in larger patient groups.
The Future of Glioblastoma Treatment
The success of this trial opens doors for combination therapies, such as pairing CAR-T cells with checkpoint inhibitors or oncolytic viruses, to further enhance anti-tumor responses. Additionally, refining delivery methods (e.g., repeated infusions or localized implants) could improve outcomes.
For now, the findings provide much-needed optimism in a field where progress has been frustratingly slow. As research continues, personalized, multi-target CAR-T therapies may one day transform glioblastoma from a death sentence into a manageable condition.
Key Takeaways
- Dual-target CAR-T cells (anti-EGFR & IL13Rα2) slowed tumor growth in 62% of recurrent GBM patients.
- Some patients survived over a year with stabilized disease—unprecedented in this aggressive cancer.
- Therapy was delivered directly to the brain via spinal fluid, enhancing effectiveness.
- Next steps: Larger trials, combination strategies, and optimizing safety.
This breakthrough underscores the potential of immunotherapy to tackle even the most resistant cancers, offering hope where options were once exhausted.
